Theravance Biopharma (NASDAQ:TBPH) Coverage Initiated at B. Riley

Key Points

• B. Riley has initiated coverage on Theravance Biopharma (NASDAQ:TBPH) with a buy rating and a price target of $28.00, suggesting a potential upside of 104.38% from the previous close.
• Additionally, other analysts, including Zacks Research and BTIG, have upgraded the stock ratings, with the average target now at $23.00, and a majority of ratings being buy or strong-buy.
• Insider trading activity showed that SVP Rhonda Farnum sold 10,000 shares at an average price of $11.39, while institutional investors have significantly increased their stakes in the company.

Research analysts at B. Riley started coverage on shares of Theravance Biopharma (NASDAQ:TBPH - Get Free Report) in a report issued on Friday, MarketBeat.com reports. The brokerage set a "buy" rating and a $28.00 price target on the biopharmaceutical company's stock. B. Riley's target price would indicate a potential upside of 98.99% from the company's previous close.

A number of other analysts have also weighed in on TBPH. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Friday, August 15th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a report on Tuesday, June 17th. Finally, BTIG Research increased their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of "Buy" and an average price target of $23.00.

Theravance Biopharma Trading Up 1.4%

Shares of NASDAQ TBPH traded up $0.20 during midday trading on Friday, hitting $14.07. The company's stock had a trading volume of 128,175 shares, compared to its average volume of 294,118. The stock has a fifty day moving average price of $12.51 and a 200 day moving average price of $10.67. Theravance Biopharma has a one year low of $7.88 and a one year high of $14.55. The firm has a market capitalization of $708.62 million, a price-to-earnings ratio of 58.68 and a beta of 0.05.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. This represents a 2.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TBPH. Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 3.5% during the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock valued at $18,579,000 after purchasing an additional 69,919 shares during the last quarter. Park West Asset Management LLC boosted its position in shares of Theravance Biopharma by 0.6% in the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after purchasing an additional 11,256 shares during the period. Geode Capital Management LLC boosted its position in shares of Theravance Biopharma by 0.4% in the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company's stock worth $9,863,000 after purchasing an additional 3,416 shares during the period. D. E. Shaw & Co. Inc. boosted its position in shares of Theravance Biopharma by 9.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock worth $7,847,000 after purchasing an additional 69,178 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Theravance Biopharma by 16.5% in the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company's stock worth $5,952,000 after purchasing an additional 76,417 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.